Analyst Ratings For NASDAQ:EGRX – Eagle Pharmaceuticals (NASDAQ:EGRX)
Today, NASDAQ:EGRX – Eagle Pharmaceuticals (NASDAQ:EGRX) stock received an upgrade by Mizuho from Underperform ➝ Neutral.
Some recent analyst ratings include
- 6/11/2018-Mizuho Upgrade from a “Underperform ➝ Neutral” rating to a “” rating.
- 1/30/2018-Piper Jaffray Companies Reiterated Rating of Buy.
- On 3/6/2018 Sander A Flaum, Director, sold 2,340 with an average share price of $53.94 per share and the total transaction amounting to $126,219.60.
- On 8/16/2017 Pete A Meyers, CFO, bought 350 with an average share price of $55.45 per share and the total transaction amounting to $19,407.50.
- On 8/9/2017 Douglas L Braunstein, Director, bought 20,400 with an average share price of $49.07 per share and the total transaction amounting to $1,001,028.00.
- On 6/12/2017 Pete A Meyers, CFO, bought 350 with an average share price of $71.49 per share and the total transaction amounting to $25,021.50.
- On 5/19/2017 David Pernock, Insider, bought 255 with an average share price of $79.69 per share and the total transaction amounting to $20,320.95.
- On 5/16/2017 David Pernock, Insider, bought 200 with an average share price of $82.24 per share and the total transaction amounting to $16,448.00.
- On 4/25/2017 Proquest Investments Iv, L.P., Major Shareholder, sold 54,180 with an average share price of $88.38 per share and the total transaction amounting to $4,788,428.40.
Recent Trading Activity for NASDAQ:EGRX – Eagle Pharmaceuticals (NASDAQ:EGRX)
Shares of NASDAQ:EGRX – Eagle Pharmaceuticals closed the previous trading session at 71.03 down -1.01 1.40% with shares trading hands.